Printer Friendly

Vitals Garners Certification for Health Care Data Security.

M2 PHARMA-August 16, 2017-Vitals Garners Certification for Health Care Data Security

(C)2017 M2 COMMUNICATIONS

- US-based healthcare shopping solutions specialist Vitals has received HITRUST CSF Certification for securing and protecting sensitive health care data, the company said.

The HITRUST CSF is the most widely used information privacy and security framework for health care organizations.

It is awarded to organisations that meet or exceed both national and international security standards for HIPAA and other personal health care data.

Vitals' solutions are accessed by millions of people each year looking for high-quality, low-cost care.

The certification encompasses the suite of Vitals' products, including VitalsChoice, SmartShopper, and Vitals.com.

Vitals, working with its HITRUST assessor, the law firm of Epstein, Becker and Green, spent over a year performing an analysis and review of existing security and privacy measures and strengthening internal policies and procedures.

The two-year certification requires continued monitoring of privacy and security controls, no reportable data security breaches and timely completion of interim reviews.

Vitals empowers everyone to shop for their health care like an expert by bringing together cost and quality transparency along with innovative consumer engagement programs to help people select high-quality, lower-cost care.

The company helps more than 120 million people each year access better, more affordable care.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 16, 2017
Words:221
Previous Article:Novo Nordisk announces changes in executive management.
Next Article:USPTO Issues Three Patents to Alexion for Soliris (eculizumab).
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters